Berecz R - Search Results

1

Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.

Dorado P, Berecz R, Peñas-Lledó EM, Cáceres MC, Llerena A. Dorado P, et al. Among authors: berecz r. Curr Drug Targets. 2006 Dec;7(12):1671-80. doi: 10.2174/138945006779025329. Curr Drug Targets. 2006. PMID: 17168842 Review.

2

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Dorado P, et al. Among authors: berecz r. Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):9-19. doi: 10.1517/17425255.3.1.9. Expert Opin Drug Metab Toxicol. 2007. PMID: 17269891 Review.

3

Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.

LLerena A, Berecz R, Dorado P, de la Garza CS, Norberto MJ, Cáceres M, Gutiérrez JR. LLerena A, et al. Among authors: berecz r. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):213-9. doi: 10.1016/s1570-0232(02)00661-x. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12450541

4

QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients.

LLerena A, Berecz R, de la Rubia A, Dorado P. LLerena A, et al. Among authors: berecz r. J Psychopharmacol. 2002 Dec;16(4):361-4. doi: 10.1177/026988110201600411. J Psychopharmacol. 2002. PMID: 12503836 Clinical Trial.

5

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.

Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A. Berecz R, et al. Eur J Clin Pharmacol. 2003 May;59(1):45-50. doi: 10.1007/s00228-003-0576-4. Epub 2003 Mar 28. Eur J Clin Pharmacol. 2003. PMID: 12682803 Clinical Trial.

6

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

LLerena A, Dorado P, Berecz R, González AP, Peñas-LLedó EM. LLerena A, et al. Among authors: berecz r. Eur J Clin Pharmacol. 2004 Feb;59(12):869-73. doi: 10.1007/s00228-003-0707-y. Epub 2004 Jan 16. Eur J Clin Pharmacol. 2004. PMID: 14726986 Clinical Trial.

7

Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.

LLerena A, de la Rubia A, Berecz R, Dorado P. LLerena A, et al. Among authors: berecz r. Pharmacopsychiatry. 2004 Mar;37(2):69-73. doi: 10.1055/s-2004-815528. Pharmacopsychiatry. 2004. PMID: 15048614

8

QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations.

Llerena A, Berecz R, Dorado P, de la Rubia A. Llerena A, et al. Among authors: berecz r. J Psychopharmacol. 2004 Jun;18(2):189-93. doi: 10.1177/0269881104042618. J Psychopharmacol. 2004. PMID: 15260906

9

Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.

Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A. Dorado P, et al. Among authors: berecz r. Clin Chem Lab Med. 2005;43(3):275-9. doi: 10.1515/CCLM.2005.046. Clin Chem Lab Med. 2005. PMID: 15843230

10

Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity.

Llerena A, Berecz R, de la Rubia A, Norberto MJ, Benítez J. Llerena A, et al. Among authors: berecz r. Ther Drug Monit. 2000 Aug;22(4):397-401. doi: 10.1097/00007691-200008000-00006. Ther Drug Monit. 2000. PMID: 10942178

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters